Description
Vidofludimus is a novel immunosuppressive drug that inhibits DHODH; inhibits IL-17 secretion in vitro independently of effects on lymphocyte proliferation.
Vidofludimus is a novel immunosuppressive drug that inhibits DHODH; inhibits IL-17 secretion in vitro independently of effects on lymphocyte proliferation.
B1633 | Vidofludimus DataSheet
Alternate Name/Synonyms: Vidofludimus; 4SC-101; 4SC 101; 4SC101; SC12267; SC 12267, SC-12267; 2-[[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid
Appearance: Solid
Formulation: N/A
CAS Number: 717824-30-1
Structure Available?: Yes
Peptide sequence: N/A
Salt Form: No
Molecular Formula: C₂₀H₁₈FNO₄
Molecular Weight: 355.36
Cell-Permeable?: Yes
Purity: >98%
Solubilities: DMSO
Handling: Protect from air and light
Country of Origin: USA
Tag Line: A novel immunosuppressive drug
MDL Number: MFCD18633262
PubChem CID: 9820008
SMILES: COC1=CC=CC(=C1)C2=CC(=C(C=C2)NC(=O)C3=C(CCC3)C(=O)O)F
InChi: 1S/C20H18FNO4/c1-26-14-5-2-4-12(10-14)13-8-9-18(17(21)11-13)22-19(23)15-6-3-7-16(15)20(24)25/h2,4-5,8-11H,3,6-7H2,1H3,(H,22,23)(H,24,25)
InChi Key: XPRDUGXOWVXZLL-UHFFFAOYSA-N
Additional Information
Storage Condition: |
-20°C |
Shipping Condition: |
Gel Pack |
Shelf Life: |
36 months |